2025 Q2 -tulosraportti
213 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 200 | - | - | ||
| 1 400 | - | - | ||
| 1 500 | - | - | ||
| 651 | - | - | ||
| 7 445 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 t sittenCircio becomes worth more than 50 billion. Hold onto the shares and don't sell if the price fluctuates.
·2 t sittenFrom the article: Within this field, transactions are most often made at the stage Circio is now. Even though the share has risen a lot, there is truly a long way to go in the share price if one compares it with the acquisitions that have been made, says Holom. We are in favor with one of the largest companies. They are active and acquire a good deal these days. Let's say we are one to two years behind those that were acquired, and that we can be there in 2027. There is no one else doing exactly what we do; Circio is the leading global player, says Wiklund. Circio must be the stock exchange's answer to Rocky Balboa. In May, almost two years ago, the biotech company was the smallest on the Oslo Stock Exchange, and its market value was as low as 13 million kroner. «Had we been a venture capital-funded, privately owned, American company, Circio's valuation would have been up to 100 times more,» said Circio CEO Erik Wiklund to Finansavisen. Now he appears to be a true prophet. Circio is valued at 1.8 billion after a rise of 1,566 percent in the last year, and trading volumes are now sky-high. On Friday, only the red-hot oil stocks Equinor, Aker BP, and Vår Energi were traded more. – It's almost unbelievable, says Wiklund now. – Catastrophic At the center is a financing agreement with Atlas Capital Markets. The American investment company offers, as they themselves write, «creative solutions for those who need money.» For Circio, it was about a convertible loan. – As it played out, Atlas was catastrophic for the company, says analyst Geir Hiller Holom at DNB Carnegie to Finansavisen. The Atlas agreement involved the continuous issuance of new shares, which put heavy pressure on the price because the shares were mostly sold immediately. At the same time, it scared away potential investors. Many found the technology exciting but stayed away because they feared continuous dilution. In addition, Atlas continuously sold shares, which amplified the pressure on the price, says Holom. Wiklund nuances. For Circio would never have survived without a contribution of 4 million a month from Atlas. – It ensured that we were able to develop the technology at a time when no one else was willing to contribute sufficient capital. They took a great risk, he says. COVERS BIOTECH: Analyst Geir Hiller Holom at DNB Carnegie is responsible for the coverage of several biotech companies. Photo: DNB Carnegie New start Now the situation has turned around. Circio has gotten rid of the Atlas financing and secured capital that will at least provide operations well into 2027. – It has been a great relief. Many investors now see the company as investable again, says Holom. At the same time, many new owners have entered the stock, which has increasingly become a favorite among retail investors.
·3 t sittenArticle in Finansavisen about Circio CEO Erik Wiklund believing the company could be valued 100 times. Now that it has gone 140 times, he believes it still has significant upside. This creates buzz and good attention around the company. There will probably be a nice rise tomorrow too with a bit of free advertising from FA.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
213 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenCircio becomes worth more than 50 billion. Hold onto the shares and don't sell if the price fluctuates.
- ·2 t sittenFrom the article: Within this field, transactions are most often made at the stage Circio is now. Even though the share has risen a lot, there is truly a long way to go in the share price if one compares it with the acquisitions that have been made, says Holom. We are in favor with one of the largest companies. They are active and acquire a good deal these days. Let's say we are one to two years behind those that were acquired, and that we can be there in 2027. There is no one else doing exactly what we do; Circio is the leading global player, says Wiklund. Circio must be the stock exchange's answer to Rocky Balboa. In May, almost two years ago, the biotech company was the smallest on the Oslo Stock Exchange, and its market value was as low as 13 million kroner. «Had we been a venture capital-funded, privately owned, American company, Circio's valuation would have been up to 100 times more,» said Circio CEO Erik Wiklund to Finansavisen. Now he appears to be a true prophet. Circio is valued at 1.8 billion after a rise of 1,566 percent in the last year, and trading volumes are now sky-high. On Friday, only the red-hot oil stocks Equinor, Aker BP, and Vår Energi were traded more. – It's almost unbelievable, says Wiklund now. – Catastrophic At the center is a financing agreement with Atlas Capital Markets. The American investment company offers, as they themselves write, «creative solutions for those who need money.» For Circio, it was about a convertible loan. – As it played out, Atlas was catastrophic for the company, says analyst Geir Hiller Holom at DNB Carnegie to Finansavisen. The Atlas agreement involved the continuous issuance of new shares, which put heavy pressure on the price because the shares were mostly sold immediately. At the same time, it scared away potential investors. Many found the technology exciting but stayed away because they feared continuous dilution. In addition, Atlas continuously sold shares, which amplified the pressure on the price, says Holom. Wiklund nuances. For Circio would never have survived without a contribution of 4 million a month from Atlas. – It ensured that we were able to develop the technology at a time when no one else was willing to contribute sufficient capital. They took a great risk, he says. COVERS BIOTECH: Analyst Geir Hiller Holom at DNB Carnegie is responsible for the coverage of several biotech companies. Photo: DNB Carnegie New start Now the situation has turned around. Circio has gotten rid of the Atlas financing and secured capital that will at least provide operations well into 2027. – It has been a great relief. Many investors now see the company as investable again, says Holom. At the same time, many new owners have entered the stock, which has increasingly become a favorite among retail investors.
- ·3 t sittenArticle in Finansavisen about Circio CEO Erik Wiklund believing the company could be valued 100 times. Now that it has gone 140 times, he believes it still has significant upside. This creates buzz and good attention around the company. There will probably be a nice rise tomorrow too with a bit of free advertising from FA.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 200 | - | - | ||
| 1 400 | - | - | ||
| 1 500 | - | - | ||
| 651 | - | - | ||
| 7 445 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
213 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenCircio becomes worth more than 50 billion. Hold onto the shares and don't sell if the price fluctuates.
- ·2 t sittenFrom the article: Within this field, transactions are most often made at the stage Circio is now. Even though the share has risen a lot, there is truly a long way to go in the share price if one compares it with the acquisitions that have been made, says Holom. We are in favor with one of the largest companies. They are active and acquire a good deal these days. Let's say we are one to two years behind those that were acquired, and that we can be there in 2027. There is no one else doing exactly what we do; Circio is the leading global player, says Wiklund. Circio must be the stock exchange's answer to Rocky Balboa. In May, almost two years ago, the biotech company was the smallest on the Oslo Stock Exchange, and its market value was as low as 13 million kroner. «Had we been a venture capital-funded, privately owned, American company, Circio's valuation would have been up to 100 times more,» said Circio CEO Erik Wiklund to Finansavisen. Now he appears to be a true prophet. Circio is valued at 1.8 billion after a rise of 1,566 percent in the last year, and trading volumes are now sky-high. On Friday, only the red-hot oil stocks Equinor, Aker BP, and Vår Energi were traded more. – It's almost unbelievable, says Wiklund now. – Catastrophic At the center is a financing agreement with Atlas Capital Markets. The American investment company offers, as they themselves write, «creative solutions for those who need money.» For Circio, it was about a convertible loan. – As it played out, Atlas was catastrophic for the company, says analyst Geir Hiller Holom at DNB Carnegie to Finansavisen. The Atlas agreement involved the continuous issuance of new shares, which put heavy pressure on the price because the shares were mostly sold immediately. At the same time, it scared away potential investors. Many found the technology exciting but stayed away because they feared continuous dilution. In addition, Atlas continuously sold shares, which amplified the pressure on the price, says Holom. Wiklund nuances. For Circio would never have survived without a contribution of 4 million a month from Atlas. – It ensured that we were able to develop the technology at a time when no one else was willing to contribute sufficient capital. They took a great risk, he says. COVERS BIOTECH: Analyst Geir Hiller Holom at DNB Carnegie is responsible for the coverage of several biotech companies. Photo: DNB Carnegie New start Now the situation has turned around. Circio has gotten rid of the Atlas financing and secured capital that will at least provide operations well into 2027. – It has been a great relief. Many investors now see the company as investable again, says Holom. At the same time, many new owners have entered the stock, which has increasingly become a favorite among retail investors.
- ·3 t sittenArticle in Finansavisen about Circio CEO Erik Wiklund believing the company could be valued 100 times. Now that it has gone 140 times, he believes it still has significant upside. This creates buzz and good attention around the company. There will probably be a nice rise tomorrow too with a bit of free advertising from FA.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 200 | - | - | ||
| 1 400 | - | - | ||
| 1 500 | - | - | ||
| 651 | - | - | ||
| 7 445 | - | - |
Välittäjätilasto
Dataa ei löytynyt